Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from December 9, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 9, 2026.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted

$36.00 – $40.00Entry zone — fair-value band

$40.71Published — price the day we called it

$52.10Target — the price the thesis aimed for

$40.74Peak — highest point inside the window, not a realized return

$22.16Window close — end-of-window price, context only

What happened

Partial

Reached 0% of the predicted growth at its peak, without hitting the target.

Peak price

$40.74

peak on December 9, 2025 — not a realized return

Peak gain

+0.1%

peak, from the publication price

Window close

$22.16

end-of-window price, context only

Days to target

—

Window

December 9, 2025 – March 9, 2026

The thesis — published December 9, 2025

Predicted growth

+28%

over the measurement window

Target price

$52.10

the price the thesis aimed for

Entry zone

$36.00 – $40.00

the fair-value band we waited for

Price at publication

$40.71

published December 9, 2025

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Hims & Hers is riding strong market interest and rising prices, but its business numbers are only modest. Recent news about buying Livewell and entering Canada prepares it for selling generic semaglutide products, which could grow sales. Because the stock looks stretched, there is a higher chance of sharp drops, so this is best for short-term traders who accept extra risk.

Primary drivers

High investor enthusiasm is pushing demand for the shares.
Direct-to-consumer telehealth can scale as more customers use it.
Livewell deal and Canada move support future weight-loss product sales.
Weak fundamentals and high valuation increase execution and valuation risk.

How it played out

HIMS: the thesis did not reach its target

Lyra published HIMS at 40.71 on 2025-12-09, with 28% expected growth and a 52.10 target. The thesis pointed to high investor enthusiasm, scalable direct-to-consumer telehealth, the Livewell deal and Canada move for future weight-loss product sales, and weak fundamentals plus high valuation as risks.

Inside the window, HIMS peaked at 40.74 on 2025-12-09, a 0.1% gain. It never reached 52.10. By 2026-03-09, it ended at 22.16. The published thesis missed: the stock did not break higher, and it finished far below the publication price.

What happened during the window

On Feb. 19, 2026, Hims & Hers announced an agreement to acquire Eucalyptus in a $1.15 billion deal, with the transaction expected to close in mid-2026. The same report said Eucalyptus had annual revenue of more than $450 million and more than 775,000 customers.

Hims & Hers is spending more than $1 billion in a push to expand globally

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals